Chip Somodevilla/Getty Images
-
Former Republican presidential candidate, entrepreneur, and author, Vivek Ramaswamy has a net worth of $800 million, according to Celebrity Net Worth.
-
The bulk of Ramaswamy’s wealth comes from his 10% stake in Roivant Sciences, a pharmaceutical company he founded.
-
He also co-founded investment firm Strive Asset Management, in which he has a stake worth more than $100 million.
-
Ramaswamy was recently appointed as co-lead of President-elect Trump’s new Department of Government Efficiency alongside Tesla CEO Elon Musk.
Former Republican presidential candidate, entrepreneur, and author Vivek Ramaswamy is nearly a billionaire, thanks to his investments in biotech and financial companies.
Ramaswamy has an estimated net worth of $800 million, according to Celebrity Net Worth. Ramaswamy was recently appointed as co-lead of President-elect Trump’s new Department of Government Efficiency alongside Tesla CEO Elon Musk.
From founding his own biotech and financial companies to his stake in private jets, here’s how Ramaswamy made his millions.
The bulk of Ramaswamy’s wealth comes from his stake in Roivant Sciences, a pharmaceutical company he founded in 2014. Roivant has subsidiaries that develop drugs and technologies to treat various medical conditions, including psoriasis and cancer.
In 2020, Japanese pharmaceutical company Sumitomo Dainippon bought ownership interests in five of Roivant’s companies for $3 billion and a 10% stake in Roivant. Ramaswamy reported more than $176 million in total income that year, including $174 million in capital gains.
Roivant went public in 2021 at a $7.3 billion valuation and has a market cap of $8.2 billion as of this writing. Ramaswamy owns about 10% in Roivant, according to Forbes. Ramaswamy stepped down as CEO of Roivant in 2021 but remained chairman until 2023 when he left to focus on his presidential campaign. The Ohio native sold $33 million worth of shares in Roivant in January 2024 to fund his presidential campaign, which was largely self-funded, per Bloomberg.
One of Roivant’s subsidiaries, Axovant, went public in 2015 with a $2.2 billion valuation—the largest U.S. biotech IPO at the time. Ramaswamy reported $37 million in capital gains on his tax return that year, with a total income of almost $39 million.
Before founding Roivant Sciences, Ramaswamy worked at QVT Financial, where he managed the company’s biotech portfolio, and earned $7 million in total compensation between 2007 to 2014.
